The document discusses floating drug delivery systems (FDDS), emphasizing their importance in enhancing oral drug bioavailability by improving gastric retention time. It categorizes FDDS into effervescent and non-effervescent types, each with specific mechanisms and formulations for drug release. The advantages include reduced side effects and improved patient compliance through decreased dosing frequency, although certain drug conditions and gastrointestinal factors can limit their effectiveness.

1. 1
FIRDOUS,
M. PHARMACY.
Floating drug delivery system

2.  Introduction
 Why Floating Drug Delivery Systems ?
 Mechanism of Floating Drug Delivery System
 Types of Floating Drug Delivery System
1. Effervescent System
2. Non-Effervescent System
 Evaluation of Floating Drug Delivery System
 Advantages
 Disadvantages
 Conclusion
2

3.  Among all diff. routes, oral has achieved more attention &
quite successful.
 This is due to fact that GI physiology provides more
flexibility then other routes.
 But in oral solids, drug absorption is unsatisfactory and
variable .
 In oral controlled releases, release time was previously not
enhanced more then 12 hrs.
3

4.  This promoted the research in this direction by enhancing
gastric retention time.
 By this method, bioavailability enhanced, drug waste
reduced & solubility increased for insoluble drugs at high
pH levels.
4

5.  Various approaches followed to enhance GR (Gastric
Retention) Time for oral dosage form.
 Floating system has low bulk density & they can float on
gastric juice in the stomach.
 They can retain drug for longer time.
 This system can enhance drug's safety and reduce side effect .
 Thus ultimately, bioavailability enhanced.
5

6. 6

7.  Mainly FDDS categorized into 2 brief Categories.
1. Effervescent System,
2. Non-Effervescent System.
 These both then further divided into sub-categories.
 Chart of FDDS classification is shown as…..
7

8. Floating Drug Delivery System
Effervescent
System
Gas
generating
system
Volatile
liquid/
vacuum
containing
system
Non-Effervescent
System
Single
Layer
Floatin
g
Tablet
Bilayer
Floatin
g
Tablet
Alginat
e Beads
Hollow/
floating
Microsp
heres
8

9.  Use of gas generating carbonates (Citric acid, tartaric
acid) to produce CO2 gas and reducing the density of the
system, this may let them float.
 Another method is, to incorporate matrix containing
liquids, which produce gas .
 Thus 2 sub types of effervescent system are..
1. Gas Generating System,
2. Volatile Liquid/Vacuum Containing System.
9

10. 1. Gas
Generati
ng
System
Intra gastric single layer
floating tablet
Intra gastric bilayer
floating tablet
Multiple unit floating pills
10

11. 2.
Volatile
liquid
/vacuum
containi
ng
System
Intra gastric floating
GIDDS
Inflatable GIDDS
Intra gastric osmotically
CDDS
11

12.  Based on mechanism of swelling of polymer or bioadhesion
to mucosal layer in GI tract.
 Gel forming or Highly swallable cellulose type of
hydrocolloids, polysaccharides & matrix forming materials
as polycarbonate, polymethacrylate, polyacrylate used.
12

13. Non
Effervesce
nt System
Single Layer Floating Tablet
Bilayer Floating Tablet
Alginate Beads
Hollow Microspheres/
Microballoons
13

14.  Floating duration
 Dissolution profiles
 Specific gravity
 Content uniformity
 Differential scanning
calorimetry
 Particle size analysis
 Flow properties
14

15. Sr
No.
Dosage
Form
Drugs
1. MICROSPHER
E
Aspirin, Griseofulvin, p-nitroglycerine, ibuprofen,
Terfinadine, Tranilast.
2. GRANULES Diclofenac sodium, Indomethacin, Prednisolone
3. FILMS Cinnarizine
4. CAPSULE Chlrdiazepoxide, Diazepam, Furosemide, L-Dopa,
Benserazide, Misoprostol, Propanolol
5. TABLET/
PILLS
Acetaminophen, ASA, Amoxicilin
Trihydrate,Ampicilin, Atenolol,
Chlorphenarimine,Cinnazirine,
Diltiazem,Flourouracil, Isosorbide Mononitrate &
dinitrate, p-aminobenzoic acid, Prednisolone,
Quinidine Gluconate,Ribiflavin 5-p,
Sotalol,Theophylline, Verapamil 15

16. 16
S.No Product Active Ingredient
1 Madopar Levodopa and benserzide
2 Valrelease Diazepam
3 Topalkan Aluminum magnesium
antacid
4 Almagate
flatcoat
Antacid
5 Liquid gavison Alginic acid and sodium
bicarbonate

17.  Used easily for drugs that absorbed specially from stomach
or proximal part of small intestine.
 Fluctuation in plasma drug are minimized, which is used for
drugs with narrow therapeutic index.
 Maximum absorption expected even at alkaline pH of the
intestine.
 FDDS improves patient compliance by decreasing dosing
frequency.
17

18.  Gastric retention is influenced by many factors such as
gastric motility, pH and presence of food. These factors are
never constant and hence the buoyancy cannot be
predicted.
 Drugs with stability, irritation and solubility problems in
GIT, not suggested for FDDS.
 Drugs that goes first pass metabolism also not used. eg.
Nifedipine.
 Drug that is if unstable in acidic condition of stomach, not
to be use.
18

19. 19
Thank you